Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cocrystal Pharma, Inc. (COCP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.15, with a market capitalisation of $22.54M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.76 to $2.03. This page covers its latest market performance, valuation, price trends and company information.
$22.54M | |
$1.21 | |
$77.40 | |
$0.76 | |
$1.17 | |
33.52K | |
60.67K | |
-- | |
$2.03 | |
$0.76 | |
-- | |
-- |
Cocrystal Pharma, Inc. (COCP) is trading at $1.19 in pre-market trading as of 2026-09-15 21:12:00, up 1.62% ($0.02) from the previous close of $1.17
Pre-market trading shows how investors are pricing COCP before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Cocrystal Pharma, Inc. (COCP) moved from $1.13 to $1.15, representing a gain of 1.33% ($0.02).
The stock traded between $1.10 and $1.29 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 55.05 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30.3%
COCP is currently trading at $1.15, placing it 30.3% of the way from its 52-week low of $0.76 to its 52-week high of $2.03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cocrystal Pharma, Inc. (COCP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.